NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $19.86 +0.22 (+1.12%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$19.77 -0.09 (-0.43%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPRX alerts:Sign Up Key Stats Today's Range$19.48▼$20.0850-Day Range$19.64▼$26.3152-Week Range$17.58▼$26.58Volume2.24 million shsAverage Volume1.39 million shsMarket Capitalization$2.42 billionP/E Ratio12.04Dividend YieldN/APrice Target$33.20Consensus RatingBuy Company Overview Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Read More Catalyst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreCPRX MarketRank™: Catalyst Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 33rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth12.11% Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 12.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 12.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.76.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.31% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.99 Percentage of Shares Shorted7.31% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.77 News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Catalyst Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest23 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.MarketBeat Follows7 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,879,369.00 in company stock.Percentage Held by Insiders10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesCatalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call TranscriptAugust 7 at 3:16 PM | seekingalpha.comCatalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business UpdateAugust 6 at 4:13 PM | globenewswire.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 9 at 2:00 AM | Crypto 101 Media (Ad)Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)August 6 at 8:03 AM | globenewswire.comComposite Rating For Catalyst Pharmaceuticals Jumps To 96August 5, 2025 | msn.comCatalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?August 5, 2025 | finance.yahoo.comCatalyst Pharmaceuticals Inc (CPRX) Q2 2025 Earnings Report Preview: What to ExpectAugust 5, 2025 | finance.yahoo.comCatalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of DirectorsAugust 4, 2025 | globenewswire.comSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $20.87 at the beginning of 2025. Since then, CPRX stock has decreased by 4.8% and is now trading at $19.86. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 40.78% and a net margin of 37.36%. Read the conference call transcript. Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (2.35%), Boston Partners (1.05%), Allianz Asset Management GmbH (0.85%) and Bank of New York Mellon Corp (0.59%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Richard J Daly, Brian Elsbernd, Philip H Coelho, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Price Target for Catalyst Pharmaceuticals$32.83 High Price Target$36.00 Low Price Target$30.00 Potential Upside/Downside+65.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.57 Trailing P/E Ratio12.04 Forward P/E Ratio10.45 P/E Growth0.8Net Income$163.89 million Net Margins37.36% Pretax Margin48.70% Return on Equity40.78% Return on Assets35.36% Debt Debt-to-Equity RatioN/A Current Ratio6.71 Quick Ratio5.96 Sales & Book Value Annual Sales$491.73 million Price / Sales4.93 Cash Flow$2.47 per share Price / Cash Flow8.03 Book Value$7.02 per share Price / Book2.83Miscellaneous Outstanding Shares121,970,000Free Float109,290,000Market Cap$2.42 billion OptionableOptionable Beta0.70 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CPRX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.